Ambrx Biopharma Inc. (AMAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMAM Stock Summary
- With a one year PEG ratio of 0.47, AMBRX BIOPHARMA INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- With a year-over-year growth in debt of 421.62%, AMBRX BIOPHARMA INC's debt growth rate surpasses 95.93% of about US stocks.
- Revenue growth over the past 12 months for AMBRX BIOPHARMA INC comes in at -61.71%, a number that bests just 2.97% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AMAM, based on their financial statements, market capitalization, and price volatility, are PRQR, OGEN, IMRX, INO, and IMGN.
- To check out AMBRX BIOPHARMA INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001836056.
AMAM Valuation Summary
- In comparison to the median Healthcare stock, AMAM's price/earnings ratio is 103.52% lower, now standing at -0.8.
- Over the past 19 months, AMAM's price/sales ratio has gone down 32.3.
Below are key valuation metrics over time for AMAM.
AMAM Stock Price Chart Interactive Chart >
AMAM Price/Volume Stats
|Current price||$1.89||52-week high||$5.33|
|Prev. close||$2.01||52-week low||$0.38|
|Day high||$2.00||Avg. volume||762,226|
|50-day MA||$1.63||Dividend yield||N/A|
|200-day MA||$2.22||Market Cap||72.99M|
Ambrx Biopharma Inc. (AMAM) Company Bio
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the Ã and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.
Most Popular Stories View All
AMAM Latest News Stream
|Loading, please wait...|
AMAM Latest Social Stream
View Full AMAM Social Stream
Latest AMAM News From Around the Web
Below are the latest news stories about AMBRX BIOPHARMA INC that investors may wish to consider to help them evaluate AMAM as an investment opportunity.
It is a pleasure to report that the Ambrx Biopharma Inc. ( NYSE:AMAM ) is up 70% in the last quarter. But that's not...
Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates this week based on the Fintel short squeeze leaderboard . Ambrx Biopharma: Clinical stage biopharmaceutical company Ambrx Biopharma (NYSE: AMAM ) tops the list for the week, moving up three places. Data shows 39% of the float short and a cost to borrow of 98.7%, both among the highest on the leaderboard. The stock was the seventh most s earched-for ticker on Benzinga Pro in the month of December, and has attracted investor attention after reporting preliminary safety … Full story availa...
Ambrx Biopharma Inc. (NYSE:AMAM) has seen 2.71 million shares traded in the last trading session. The company, currently valued at $62.90M, closed the last trade at $2.27 per share which meant it gained $0.64 on the day or 39.26% during that session. The AMAM stock price is -319.38% off its 52-week high price of $9.52 … Ambrx Biopharma Inc. (AMAM) Shares Are Down -74.86% YTD Read More »
Ambrx Biopharma Inc. (NYSE:AMAM) price on Friday, December 23, fall -1.22% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.62. A look at the stock’s price movement, the close in the last trading session was $1.64, moving within a range at $1.45 and $1.74. Turning to its … What Can Ambrx Biopharma Inc. (NYSE: AMAM) Expect In 2022? Read More »
Ambrx Biopharma (NYSE: AMAM) was down by more than 8% in pre-market trading on Monday as the clinical-stage biopharma company announced that it had…
AMAM Price Returns